Pfizer (PFE) stock falls, and its COVID vaccine peers such as Moderna (MRNA) and Novavax (NVAX) also drop as the company ...

We came across a bullish thesis on Novavax, Inc. on Ridire Research’s Substack. In this article, we will summarize the bulls’ ...

Novavax (NVAX) has been struggling to convince the market that its COVID era gains can translate into a durable vaccine business, and the stock’s recent slide reflects those doubts. See our latest ...

Shares of several major vaccine makers lost ground Monday following a report U.S. vaccine approval rules could become stricter.

The FDA’s top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.

Shares of two major Covid-19 vaccine makers declined Monday after a Food and Drug Administration official [claimed the shots]( ...

Vinay Prasad, the head of the US FDA's Center for Biologics Evaluations and Research which oversees vaccines, said that future vaccine approvals will face stricter standards in light of the deaths of ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Novavax, with a price target of $6.00. The company’s shares closed yesterday at $6.69. Claim ...

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead ...

Shares of Novavax Inc. NVAX advanced 1.20% to $6.74 Wednesday, on what proved to be an all-around positive trading session ...

Shares of Novavax Inc. NVAX shed 1.77% to $6.66 Tuesday, on what proved to be an all-around mixed trading session for the ...